Cornerstone Buys EKR Therapeutics To Expand Hospital Growth Strategy
This article was originally published in The Pink Sheet Daily
Cornerstone gains two commercial products for the acute-care hospital setting, Cardene and Retavase, with the acquisition of EKR Therapeutics for $125 million upfront and potential milestones.
You may also be interested in...
With a would-be competitor from Discovery Labs stalled at FDA, approved lung surfactant Curosurf sits at the center of equity, cash tie-up.
After completing a reverse merger with Critical Therapeutics last year, Cornerstone has retooled the marketing message for the asthma medication and ramped up commercial support.
The company said it will update investors on the path forward for zuranolone in major depressive disorder after finalizing discussions with the US FDA. It would not confirm if a meeting had taken place yet.